Clos P*2/Cl Oth*5/H.Somnus Kb

Verify with FDA CVM →

13 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
13
Total Reports
11
Deaths Reported
8460.0%
Death Rate

Active Ingredients

Clos P*2/Cl Oth*5/H.Somnus Kb

Administration Routes

SubcutaneousUnknown

Species Affected

Cattle 13

Most Affected Breeds

Cattle (other) 5
Aberdeen Angus 4
Hereford cattle 2
Cattle (unspecified) 2

Most Reported Reactions

Death 8
Lack of efficacy - NOS 5
Lack of efficacy (bacteria) - NOS 3
NT - Abnormal necropsy finding NOS 2
Increased mortality rate 1
General illness 1
Weight loss 1
Abnormal necropsy finding 1
NT - fibrinous (broncho) pneumonia/fibrinous pleuropneumonia 1
Lameness 1
Skin swelling 1
Death by euthanasia 1

Outcome Breakdown

Died
10 (38.5%)
Recovered/Normal
8 (30.8%)
Ongoing
5 (19.2%)
Euthanized
2 (7.7%)
Outcome Unknown
1 (3.8%)

Data Summary

Metric Value
Total adverse event reports 13
Reports involving death 11
Case-fatality rate (reported events) 8460.0%
Distinct species in reports 1
Distinct breeds in reports 4
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Clos P*2/Cl Oth*5/H.Somnus Kb Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 13 adverse event reports referencing Clos P*2/Cl Oth*5/H.Somnus Kb, including 11 reports in which the animal died — a 8460.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Clos P*2/Cl Oth*5/H.Somnus Kb. Reported administration routes include Subcutaneous, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Clos P*2/Cl Oth*5/H.Somnus Kb reports are Cattle (13 reports), with Cattle accounting for the largest share. Within those species, Cattle (other) (5), Aberdeen Angus (4), Hereford cattle (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Clos P*2/Cl Oth*5/H.Somnus Kb are Death (8), Lack of efficacy - NOS (5), Lack of efficacy (bacteria) - NOS (3), NT - Abnormal necropsy finding NOS (2). Of the 26 reports with a coded outcome, Died is the leading category at 38.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Clos P*2/Cl Oth*5/H.Somnus Kb.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial